How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS: Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA1c. In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both have been identified as important determinants of the heart failure benefits of these drugs in trials of patients with type 2 diabetes.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [32]
In the citing paper
“Those that appear particularly plausible include effects on volume status, natriuresis, expansion of red blood cell mass, and myocardial energetics (34,36,59,62,64).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
In the citing paper
“Thus, the mechanisms by which SGLT2 inhibitors reduce the risk for HF are not attributable to improved glycemic control (59).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
Citations
Cites
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532 · cited 2×
“A traditional mediation analysis as originally proposed by Baron and Kenny (12) was used, taking the time-dynamic evolvement of both the potential mediators and the outcome CV death into account.”
Method(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundSelf-citationLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155 · cited 1×
“Therefore, many participants in this trial likely had unrecognized left ventricular dysfunction, particularly diastolic dysfunction, which may eventually lead to clinical heart failure with preserved ejection fraction (25).”
Background
Research works printed but not linked: 2
- Fitchett, Further exploration of the cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease in EMPA-REG OUTCOME, J Am Coll Cardiol
- Boehringer Ingelheim. Empagliflozin (Jardiance®) to be studied in chronic kidney disease. 2017. Available from https://www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 6 September 2017
Cited by
Items 301–400 of 762
Giaccari, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13814 · Cited by 23
Young, S. L., Ryan, L., MULLINS, T. P., Flint, M., Steane, S. E., Walton, S. L., Bielefeldt‐Ohmann, H., Carter, D. A., Reichelt, M. E., & Gallo, L. A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.738594 · Cited by 26
Ekanayake, P. S., & Mudaliar, S. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14562 · Cited by 25
“A mediation analysis of the EMPAREG-Outcome study suggested that an increase in haematocrit was an important mediator of the cardio-renal benefits of empagliflozin.(51) It is possible that this increase in haematocrit results from the modest diuretic effect of SGLT2 inhibitors causing haemoconcentration.”
MethodA Comprehensive Review of Clinical Studies Applying Flow-Mediated Dilation
Ahn, Y., Aung, N., & Ahn, H. (2024) · Diagnostics · doi:10.3390/diagnostics14222499 · Cited by 21
“In fact, substantial increases have been reported in hematocrit and hemoglobin in a post hoc analysis of the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG Outcomes) study [52].”
Brata, R. D., Paşcalău, A. V., Frățilă, O., Paul, I. L., Muresan, M. M., Cămărășan, A., & Ilias, T. I. (2024) · Healthcare · doi:10.3390/healthcare12232464 · Cited by 21
“In All these data can explain the beneficial effects observed in patients with heart failure in large, randomized controlled trials when they were administered with SGLT2 inhibitors. the DAPA-HF trial, a 30% reduction in the risk of worsening heart failure has been observed in patients with or…”
Kuo, S., Ye, W., Duong, J. J., & Herman, W. H. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.040 · Cited by 22
Liu, J., Pong, A., Gallo, S., Darekar, A., & Terra, S. G. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0856-7 · Cited by 21
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 23
Chin-yee, B., Matyashin, M., Cheong, I., Bhai, P., Lazo-langner, A., Almanaseer, A., Kawata, E., Levy, M., Stuart, A., Lin, H., et al. (2022) · CMAJ Open · doi:10.9778/cmajo.20210322 · Cited by 17
“9 Literature on more severe cases of erythrocytosis associated with SGLT2 inhibitor use is limited to a small number of case reports; 12–14 however, the findings of our study suggest that this may be a more widespread phenomenon and that SGLT2 inhibitors may be a significant, underrecognized cause…”
Skeik, N., Elejla, S. A., Sethi, A., Manunga, J. M., & Mirza, A. K. (2023) · Vascular Medicine · doi:10.1177/1358863x221143811 · Cited by 22
Managing Anemia: Point of Convergence for Heart Failure and Chronic Kidney Disease?
Buliga-Finiș, O. N., Ouatu, A., Tănase, D. M., Gosav, E. M., Isac, P. N. S., Richter, P., & Rezuș, C. (2023) · Life · doi:10.3390/life13061311 · Cited by 23
“It is also known from the proven efficacy of gliflozines that by stimulating hypoxiainducible factors, HIF-1 induces expression of hemoxygenase 1, a tissue-protective gene [70], and HIF-2 activation enhances erythropoietin expression [71] and release from renal interstitial cells, which, together with the diuretic eff…”
BackgroundRodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 22
“12, 16 addition , meta-regression meta-regression analyses of various glycemic trials have shown a significant correlation lowering HbA1c and Compared with the prior meta-regression analyses investigating mediation mechanisms for GLP-1RAs and SGLT2i, we were able to include data from newer, more…”
BackgroundMethodInfluentialHypertension in diabetes care: emerging roles of recent hypoglycemic agents
Tanaka, A., & Node, K. (2021) · Hypertension Research · doi:10.1038/s41440-021-00665-7 · Cited by 21
Ersbøll, M. K., Jürgens, M., Hasbak, P., Kjær, A., Wolsk, E., Zerahn, B., Brandt, N., Gæde, P., Rossing, P. R., Faber, J. O., et al. (2021) · International journal of cardiac imaging · doi:10.1007/s10554-021-02443-5 · Cited by 21
Self-citationLiu, G., Qiu, Y., You, N., Yu, M., Chen, W., Sun, T., Qin, Z., Han, M., Xue, Z., Liang, X., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf026 · Cited by 20
Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females
Doi, Y., Hamano, T., Yamaguchi, O., & Isaka, Y. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016320 · Cited by 21
Empagliflozin—A New Chance for Patients with Chronic Heart Failure
Kowalska, K., Walczak, J., Femlak, J., Młynarska, E., Franczyk, B., & Rysz, J. (2021) · Pharmaceuticals · doi:10.3390/ph15010047 · Cited by 24
“[29] The promising results of this study aroused the researchers’ interests and provided a starting point to investigate the efficacy of empagliflozin in patients without diabetes, resulting in Empagliflozin Outcome trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced).”
BackgroundResultInfluentialOstrominski, J. W., & Vaduganathan, M. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.04.035 · Cited by 21
You, Y., Zhao, Y., Chen, M., Pan, Y., & Luo, Z. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01182-y · Cited by 22
“Similarly, removing the study by Inzucchi et al. [34] yielded a projected SMD of − 1.58 (95% CI − 3.70, 0.54).”
BackgroundResultInfluentialScholtes, R. A., van Raalte, D. H., Correa‐Rotter, R., Toto, R. D., Heerspink, H. J. L., Cain, V. A., Sjöström, C. D., Sartipy, P., & Stefánsson, B. V. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13923 · Cited by 20
“cardiac haemodynamics.(23) For example, Inzucchi et al showed in a mediation analysis of the EMPA-REG OUTCOME trial that the change in haematocrit from baseline mediated 51.”
BackgroundCardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Lo, C. W. H., Fei, Y., & Cheung, B. M. Y. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.19 · Cited by 22
Kolkailah, A. A., Wiviott, S. D., Raz, I., Murphy, S. A., Mosenzon, O., Bhatt, D. L., Leiter, L. A., Wilding, J. P. H., Gause‐Nilsson, I. A. M., Sabatine, M. S., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1668 · Cited by 23
Wong, C. K. H., Lau, K. T. K., Tang, E. H. M., Lee, C., Lee, C. Y. Y., Woo, Y. C., Au, I. C. H., Tan, K. C. B., & Lui, D. T. W. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01520-w · Cited by 21
“Interestingly, mediation analyses have recently identified increases in haematocrit, haemoglobin or erythrocyte concentration as the most important mediators of SGLT2i in reducing the risks of heart failure (HF) and cardiovascular death among T2D patients [15, 16].”
BackgroundResultKitada, M., Hirai, T., & Koya, D. (2020) · Diabetology International · doi:10.1007/s13340-020-00444-8 · Cited by 19
Jiang, C., Zhao, Z., Yang, Z., Wang, Y., Yang, X., Xu, H., Guo, H., Wang, C., He, L., Xia, S., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.077447 · Cited by 21
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
Curtain, J. P., Adamson, C., Docherty, K. F., Jhund, P. S., Desai, A. S., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Swedberg, K. B., Zile, M. R., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.12.012 · Cited by 19
Ferrannini, E., Solini, A., Baldi, S., Scozzaro, T., Polidori, D., Natali, A., & Hansen, M. K. (2023) · Diabetes · doi:10.2337/db23-0448 · Cited by 19
Self-citationTziastoudi, M., Pissas, G., Golfinopoulos, S., Filippidis, G., Dousdampanis, P., Eleftheriadis, T., & Stefanidis, I. (2023) · Life · doi:10.3390/life13122338 · Cited by 21
FITCHETT, D. H. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.40 · Cited by 19
“A mediation analysis indicates that more than 50% of the reduction of CV mortality and reduced HF admission was related to the observed increase in haematocrit.(45) The sustained 4% increase of haematocrit observed in patients receiving empagliflozin was likely due to an estimated 7% reduction of plasma volume, which…”
BackgroundMethodInfluentialSelf-citationThe Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 20
“In the EMPA-REG OUTCOME trial, 50% of the cardiovascular benefit was attributed to haemoconcentration [22], and further trials have suggested that in comparison to standard diuretic therapy, SGLT2 inhibitors may deplete interstitial rather than intravascular fluid as a potential rationale for benefit [23,24].”
BackgroundDapagliflozin for the treatment of chronic kidney disease
Kurata, Y., & Nangaku, M. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099373 · Cited by 21
Pistelli, L., Parisi, F., Correale, M., Cocuzza, F., Campanella, F., Ferrari, T. D., Crea, P., Sarro, R. D., Cognata, O. M. L., Ceratti, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010379 · Cited by 22
“Osmotic diuresis and natriuresis induced by SGLT-2i may help maintain the correct load condition, resulting in an improvement in blood volume [28,29].”
BackgroundMethodErythrocytosis induced by sodium-glucose cotransporter-2 inhibitors
Chin-Yee, B. H., Solh, Z., & Hsia, C. C. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.76686 · Cited by 19
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Tanaka, A., & Node, K. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01191-5 · Cited by 19
Obstructive Sleep Apnea and Type 2 Diabetes: An Update
Gentile, S., Monda, V. M., Guarino, G., Satta, E., Chiarello, M., Caccavale, G., Mattera, E., Marfella, R., & Strollo, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155574 · Cited by 24
“…cardiac autonomic neuropathy (CAN), cardiovascular defects, and renal dysfunction [125]; (ii) direct benefits on renal function [126,127] preventing CAN from entering a renal dysfunction-related vitious circle [128,129]; and (iii) increased Ht expected to reduce nocturnal hypoxia [130–133].”
Bossi, A. C., Forloni, F., & Colombelli, P. L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00844-8 · Cited by 18
Treating Hyperuricemia: The Last Word Hasn’t Been Said Yet
Russo, E., Verzola, D., Leoncini, G., Cappadona, F., Esposito, P. B., Pontremoli, R., & Viazzi, F. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040819 · Cited by 18
“While the exact mechanism, in addition to glycosuria, by which SGTL2 inhibitors are thought to reduce SUA levels is not well understood, the hypothesis that this effect is part of the CV and renal protection induced by SGLT2 inhibitors is evoked by the mediation analysis undertaken in EMPAREG OUTCOME, suggesting that…”
MethodThe impact of diabetes on heart failure development: The cardio-renal-metabolic connection
Valensi, P. E., Prévost, G., Pinto, S., Halimi, J., & Donal, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108831 · Cited by 20
Leoncini, G., Barnini, C., Manco, L., Nobili, A., Dotta, D., Penso, M., Russo, E., Cappadona, F., Viazzi, F. C., & Pontremoli, R. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac075 · Cited by 18
Lehrke, M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.023 · Cited by 18
“Still, blood glucose lowering did not predict the prognostic benefit of SGLT2 inhibition in the EMPA-REG OUTCOME trial (7).”
BackgroundSGLT2 inhibitors and diuretics in heart failure: clicking reset on the renal volume setpoint?
Borlaug, B. A., & Testani, J. M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad345 · Cited by 18
Yamada, T., Sakaguchi, K., Okada, Y., Miura, H., Otowa‐Suematsu, N., So, A., Komada, H., Hirota, Y., Ohara, T., Kuroki, Y., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00474-2 · Cited by 17
Rasalam, R. R., Atherton, J. J., Deed, G., Molloy‐Bland, M., Cohen, N. D., & Sindone, A. P. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13483 · Cited by 19
“Similarly, reduced uric acid levels, and increased erythrocyte and haemoglobin levels, were identified as important mediators of the effects of canagliflozin on HF events in the CANVAS trial programme, although haematocrit had a smaller mediating effect in this study compared with the EMPA-REG OUTCOME trial.(65,66) In…”
BackgroundResultLam-Chung, C. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1174692 · Cited by 20
“9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means (47).”
ResultJahn, L. A., Hartline, L. M., Nguyen, T. T. D., Aylor, K. W., Horton, W. B., Liu, Z., & Barrett, E. J. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00267.2023 · Cited by 17
Cersosimo, A., Salerno, N., Sabatino, J., Scatteia, A., Bisaccia, G., Rosa, S. D., Dellegrottaglie, S., Bucciarelli‐Ducci, C., Torella, D., & Leo, I. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02181-7 · Cited by 17
Kuriyama, S. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1673-0 · Cited by 17
Coleman, R. L., Gray, A. M., Broedl, U. C., FITCHETT, D. H., George, J. T., Woerle, H. J., Zinman, B., & Holman, R. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14017 · Cited by 17
“mediated outcomes is supported by an exploratory mediation analysis of the EMPA-REG OUTCOME trial.(29) This mediation analysis, which used multivariable models incorporating effects of empagliflozin on haematocrit, fasting glucose, uric acid and urine albumin:creatinine ratio, showed that the most important mediators…”
MethodSelf-citationQu, W., Li, Y., Liu, X., Xu, T., & Tian, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.630820 · Cited by 18
Cardiovascular benefit of SGLT2 inhibitors
Mohebi, R., & Januzzi, J. L. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1993439 · Cited by 17
Li, Y., Hu, H. Z., Zheng, Y., Donahoo, W. T., Guo, Y. M., Xu, J., Chen, W., Liu, N., Shenkman, E. A., Bian, J., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20054036 · Cited by 18
“Contextual-level SDoH refers to the broader social and built factors within community or region that influence health outcomes, and are increasingly recognized as a vital source of information to develop healthcare policies designed to improve population health management and value-based care [14,15].”
BackgroundPacker, M. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.01.016 · Cited by 17
Canagliflozin and iron metabolism in the CREDENCE trial
Koshino, A., Heerspink, H. J. L., Jongs, N., Badve, S. V., Arnott, C. G., Neal, B. C., Jardine, M., Mahaffey, K. W., Pollock, C. A., Perkovic, V., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae198 · Cited by 17
“Additionally, mediation analyses indicate that changes in hemoglobin and hematocrit are the most important statistical mediators of the benefits of SGLT2 inhibitors on cardio-vascular outcomes [29 –31 ].”
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Aguiar‐Neves, I., Santos‐Ferreira, D., & Fontes‐Carvalho, R. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401001 · Cited by 16
A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome
Sano, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065983 · Cited by 18
“Of these parameters, Hct was most strongly related to the reduction in cardiovascular death [5,6].”
BackgroundGosmanov, A. R., Gemoets, D. E., & Schumacher, K. A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02350-1 · Cited by 17
“There is increasing and reproducible evidence that sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use is associated with modest but significant increase in hematocrit level which could be one of the mechanisms of cardiovascular benefits of this class of anti-diabetic agents [1–3].”
Effect of SGLT2 inhibitors on anemia and their possible clinical implications
Cases, A., Cigarrán, S., Górriz, J. L., & Núñez, J. E. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.03.011 · Cited by 26
“This favors functional iron deficiency, decreasing iron availability in the bone marrow and at the myocardial level.”
BackgroundSGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review
Sloan, L. A. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2418795 · Cited by 19
“This improvement in hemoglobin may contribute to the mechanism by which these agents confer cardiovascular and kidney benefits in treated patients by reducing ischemia in these two hypermetabolic organs [38,44,45].”
Bouter, K. E. C., van Bommel, E. J. M., Jansen, H., van Harskamp, D., Schierbeek, H., Ackermans, M. T., Serlie, M. J. M., Schimmel, A. W. M., Nieuwdorp, M., Dallinga‐Thie, G. M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13990 · Cited by 19
“This reduction in plasma volume, as well as salutary effects on blood pressure, body weight and uric acid, probably drives the CV benefit of SGLT-2 inhibitors in adults with type 2 diabetes.(10,11) Other possible explanations include a switch from carbohydrates towards free fatty acid (FFA) and ketone bodies as myocar…”
BackgroundSridhar, V. S., Dubrofsky, L., Boulet, J., & Cherney, D. Z. I. (2020) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2020-0100 · Cited by 24
Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status
Lorenzo, M., Jacobs-Cachá, C., Palau, P., Amiguet, M., Seller, J., Núñez, E., de la Espriella, R., Górriz, J. L., Miñana, G., Sanchís, J. M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.07.010 · Cited by 19
Zoungas, S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13968 · Cited by 17
“only a modest proportion (23%-29%) of the overall cardiovascular benefit was attributable to glucose lowering.(32) A further mediation analysis of the SUSTAIN 6 trial has also raised concerns regarding the”
BackgroundKubica, J., Kubica, A., Grzelakowska, K., Stolarek, W., Grąbczewska, Z., Michalski, P., Niezgoda, P., Bartuś, S., Budaj, A., Dąbrowski, M., et al. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0133 · Cited by 16
“Cardiovascular mortality and all-cause mortality were significantly decreased regardless of a diabetes diagnosis only with dapagliflozin [35], while in patients with type 2 diabetes, only with empagliflozin [12].”
BackgroundBanerjee, D., Sabe, S. A., Xing, H., Xu, C., Sabra, M., Harris, D. D., Broadwin, M., Abid, M. R., Usheva, A., Feng, J., et al. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.08.017 · Cited by 17
Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01229-0 · Cited by 15
“The present study was consistent with many previous studies and showed that SGLT2i significantly decreased uric acid in T2D patients [63, 64].”
BackgroundResultYu, J., Zhou, Z., Mahaffey, K. W., Matthews, D. R., Neuen, B. L., Heerspink, H. J. L., Jardine, M., Li, J., Perkovic, V., Neal, B. C., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.09.050 · Cited by 16
Nakamura, I., Maegawa, H., Tobe, K., & Uno, S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1817388 · Cited by 18
“9%, respectively, of the effect of empagliflozin vs placebo on the risk of cardiovascular death [50].”
Backgroundder Beek, A. B. V. D. A., Koomen, J. V., Dekkers, C. C. J., Barbour, S. J., Boulton, D. W., Gansevoort, R. T., Greasley, P. J., Gafor, A. H. A., Laverman, G. D., Li, Q., et al. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00956-1 · Cited by 17
Matsuba, I., Takihata, M., Takai, M., Maeda, H., Kubota, A., Iemitsu, K., Umezawa, S., Obana, M., Kaneshiro, M., Kawata, T., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14508 · Cited by 16
Murashima, M., Tanaka, T., Kasugai, T., Tomonari, T., Ide, A., Ono, M., Mizuno, M., Suzuki, T., & Hamano, T. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13717 · Cited by 17
STOUGAARD, E. B., Rossing, P. R., Cherney, D. Z. I., Vistisen, D., & Persson, F. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108257 · Cited by 15
Succurro, E., Vizza, P., Papa, A., Miceli, S., Cicone, F., Fiorentino, T. V., Sciacqua, A., Andreozzi, F., Veltri, P., Cascini, G. L., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14816 · Cited by 16
“A mediation analysis from the EMPA-REG OUTCOME trial has suggested that increases in haematocrit and haemoglobin accounted for approximately 50% of the observed clinical benefit of the empagliflozin treatment.(53) Thus, a higher haematocrit induced by empagliflozin treatment might contribute to deliver more oxygen to…”
MethodSGLT2 Inhibitors and Peripheral Vascular Events
Marchiori, E., Rodionov, R. N., Peters, F., Magnussen, C., Nordanstig, J., Gombert, A., Spanos, K. T., Jarzebska, N., & Behrendt, C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.001 · Cited by 16
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
Ferrannini, G., Savarese, G., & Cosentino, F. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.009 · Cited by 13
Effect of high-fat diet and empagliflozin on cardiac proteins in mice
Pan, X., Chen, S., Chen, X., Ren, Q., Yue, L., Niu, S., Li, Z., Zhu, R., Chen, X., Jia, Z., et al. (2022) · Nutrition & Metabolism · doi:10.1186/s12986-022-00705-0 · Cited by 16
Cases, A., Cigarrán, S., Górriz, J. L., & Núñez, J. E. (2023) · Nefrología · doi:10.1016/j.nefro.2023.11.001 · Cited by 17
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
Liu, H., Sridhar, V. S., Perkins, B. A., Rosenstock, J., & Cherney, D. Z. I. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01471-2 · Cited by 14
Ferrannini, G., Savarese, G., & Rydén, L. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108796 · Cited by 14
Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
Ferrannini, G., Rosenthal, N. R., Hansen, M. K., & Ferrannini, E. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01558-w · Cited by 15
“Conceptually, this data analysis is akin to mediation analysis, which has been done with canagliflozin, separately for HF [32] and the renal outcome [33], and with empagliflozin for CV mortality [34].”
BackgroundSelf-citationYu, H., Tang, W., Greasley, P. J., Penland, R. C., Boulton, D. W., & Hallow, K. M. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1769 · Cited by 16
Chung, M., Hsu, H., Chang, C., Hung, P., Hsiao, P., Wu, L.-Y., Wu, M., Shieh, J., & Chung, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-13760-7 · Cited by 14
The Role of Sodium in Diabetic Cardiomyopathy
Doliba, N. M., Babsky, A. M., & Osbakken, M. D. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01473 · Cited by 14
Castillo, R. L., Farías, J. G., Sandoval, C., González‐Candia, A., Figueroa, E. G., Quezada, M., Cruz, G., Llanos, P., Jorquera, G., Kostin, S., et al. (2024) · Antioxidants · doi:10.3390/antiox13111388 · Cited by 17
Zheng, R., Song, W., Lu, J. L., Yuan, M., Sun, X., & Lu, C. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02600-3 · Cited by 14
“This reduction in serum uric acid contributes, at least in part, to the decreased cardiovascular mortality associated with SGLT2i [61].”
Watada, H., Yamauchi, T., Yamamoto, F., Taniguchi, A., Yarush, L., Heilmann, C. J., & Yasui, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1782884 · Cited by 13
Hailat, M. M., Zakaraya, Z. Z., Al-Ani, I. H., Meanazel, O. T. A., Al‐Shdefat, R., Anwer, M. K., Saadh, M. J., & Dayyih, W. A. (2022) · Pharmaceuticals · doi:10.3390/ph15020193 · Cited by 13
“For these purposes, it can be used as 10 mg orally every day and could be elevated to 25 mg/day if needed and afforded [6,7].”
MethodKoufakis, T., Liberopoulos, E. N., & Kotsa, K. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00527-8 · Cited by 13
“In support of this perspective, it was found that the reduced risk of CV death seen in EMPAREG-OUTCOME was independent of improvements in classical risk factors for atherosclerosis, such as glycated hemoglobin, blood pressure, or low-density lipoprotein cholesterol (LDL-C) [18].”
BackgroundPractical Guidance for the Use of SGLT2 Inhibitors in Heart Failure
Cavallari, I., Crispino, S. P., Segreti, A., Ussia, G. P., & Grigioni, F. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00601-9 · Cited by 15
“In the case of a normal glomerular filtration rate (GFR) and blood glucose levels up to 180 mg/dL, glomeruli reabsorb all the filtered glucose; however when the glucose levels are above 220 mg/dL, there is a linear increase in glycosuria [16].”
BackgroundBAJAJ, H. S., Aljabri, B. A., & Verma, S. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000562 · Cited by 14
Red blood cell volume is not decreased in ESA-naive anemic chronic kidney disease patients
Lundby, C., Ponte, B., Lundby, A., Robach, P., & de Seigneux, S. (2018) · Physiological Reports · doi:10.14814/phy2.13900 · Cited by 13
Budoff, M. J., Davis, T. M. E., Palmer, A. G., Frederich, R. C., Lawrence, D. E., Liu, J., Gantz, I., & Derosa, G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01033-x · Cited by 13
Wolsk, E., Jürgens, M., Schou, M., Ersbøll, M. K., Hasbak, P., Kjær, A., Zerahn, B., Brandt, N., Gæde, P., Rossing, P. R., et al. (2022) · Diabetes · doi:10.2337/db21-0721 · Cited by 13
Self-citationHuang, C., Wang, W., Sung, S., Chen, C., Lip, G. Y. H., Cheng, H., & Chiang, C. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14819 · Cited by 13
Scholtes, R. A., Mosterd, C. M., Hesp, A. C., Smits, M. M., Heerspink, H. J. L., & van Raalte, D. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14864 · Cited by 14
“One of the underlying factors may be volume contraction, secondary to (osmotic) diuresis, which leads to a reduction in preload and afterload.(20,41) In the current study, compared with placebo, empagliflozin induced a significant reduction in extracellular fluid together with an increase in serum albumin, suggesting…”
BackgroundEstimated plasma volume and mortality: analysis from NHANES 1999–2014
Marawan, A., & Qayyum, R. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01606-z · Cited by 13
Nashawi, M., Sheikh, O., Battisha, A., Ghali, A. N., & CHILTON, R. J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10046-w · Cited by 13
“Commentaries in the literature have sought to explain the benefits observed in EMPA-REG, with primary attributions given to differences in plasma volume and optimization of oxygen metabolism that optimize the hemodynamic status of patients receiving SGLT2i[22, 23].”
BackgroundZhang, Q., Deng, Z., Li, T., Chen, K., & Zeng, Z. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1280547 · Cited by 14
Marques, P. S., Mavrakanas, T. A., Guida, J., Gédéon, T., Emami, A., Alaamiri, A., Ho, D., Possik, E., Zhang, G. K., Tsoukas, M. A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15691 · Cited by 13
“23 The relatively small number of patients seen in the 40-month period since the start of our clinic reflects the challenges encountered (D) Haemoglobin (Hb).”
Kunutsor, S. K., Seidu, B. S., & Seidu, S. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.007 · Cited by 12
Metadata
- Authors
- Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., Hantel, S., Bluhmki, E., & Lachin, J. M.
- Affiliations
- Yale University (US)
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Universitätsklinikum Würzburg (DE)
- Istituto di Fisiologia Clinica (IT)
- University of Freiburg (DE)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (Germany) (DE)
- George Washington University (US)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-04
- Volume
- 41
- Issue
- 2
- Pages
- 356-363
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2772204795
- Cited by
- 740
- References
- 33
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 71 · 2023: 83 · 2022: 103 · 2021: 109 · 2020: 139 · 2019: 96 · 2018: 56
- FWCI
- 62.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Eisai
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, cardiovascular mortality, mediation analysis, type 2 diabetes, EMPA-REG OUTCOME trial, hematocrit, hemoglobin, plasma volume, uric acid, fasting blood glucose, HbA1c, urine albumin-creatinine ratio, SGLT2 inhibitors
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dose-Response Relationship, Drug, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Risk Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.